Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Glaxo prioritizes seven “power” brands globally and also will invest in boosting sales of 12 “core” brands in its consumer JV with Novartis, says division head Emma Walmsley. The combination of the two firms’ consumer products puts the JV atop the OTC/wellness market in 36 countries.

You may also be interested in...



ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value

The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.

Alli Return In U.S. Fattens Glaxo’s Consumer Outlook

GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.

Novartis OTC Plant Troubled By Quality Failures A Year After Shutdown

FDA recorded nine observations – many of them repeats from 2011 and 2012 – on a form 483 during its early 2013 visit to Novartis Consumer Health’s facility in Lincoln, Nebraska. The observations cited inadequate consumer complaint handling and container closure stability testing.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel